Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).

GlobeNewsWire • Jan 7, 2026

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.

GlobeNewsWire • Dec 23, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $402.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

GlobeNewsWire • Dec 11, 2025

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday

An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.

The Motley Fool • Dec 10, 2025

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one year, providing financial flexibility for late-stage trials and regulatory submissions. DYNE-101 and DYNE-251 both show promising safety and efficacy data, with potential accelerated FDA submissions targeted for late 2026.

Seeking Alpha • Dec 10, 2025

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter.

The Motley Fool • Dec 9, 2025

Why Dyne Therapeutics Stock Tanked on Tuesday

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares.

The Motley Fool • Dec 9, 2025

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.

GlobeNewsWire • Dec 10, 2025

Why Dyne Therapeutics Stock Was Blasting Higher Today

Its No. 1 drug candidate did well in a clinical trial. It met both its primary and secondary endpoints.

The Motley Fool • Dec 8, 2025

Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript

Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript

Seeking Alpha • Dec 8, 2025